Skip to content

Powdered phosphate lowering medicine for Indian patients on hemodialysis.

Efficacy and safety of sevelamer carbonate vs. calcium acetate in patients with chronic renal disease on dialysis

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2015/11/006342
Enrollment
50
Registered
2015-11-04
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- CHRONIC RENAL FAILURE ON MAINTENANCE HEMODIALYSIS

Interventions

Intervention1: SEVELAMER CARBONATE: It is a cation that binds to negatively charged phosphorus ion effectively. It is a non selective ion exchanger.it is given by the oral route. It comes in a sachet

Sponsors

emcure pharmaceuticals
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients with the diagnosis of chronic renal disease undergoing hemodialysis for at least 6 weeks

Exclusion criteria

Exclusion criteria: Hypercalcaemia, Significant gastrointestinal disorder (including known active peptic ulcer, Crohnâ??s disease, ulcerative colitis, irritable bowel syndrome, GI motility disorder),Current malignancy, Pregnant and lactating women, Known hypersensitivity to phosphate binders

Design outcomes

Primary

MeasureTime frame
LOWERING IN SERUM PHOSPHORUSTimepoint: 0 week, 4 week, 5 week, 9 week

Secondary

MeasureTime frame
REDUCTION IN LOW DENSITY LIPOPROTEIN, TRIGLYCERIDE, TOTAL CHOLESTROL AND C-REACTIVE PROTEINTimepoint: 0 WEEK, 4 WEEK, 5 WEEK, 9 WEEK

Countries

India

Contacts

Public ContactDr Akanksha Grace William

BABA FARID UNIVERSITY OF HEALTH SCIENCES

narulajasleen03@gmail.com9814917365

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026